相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
Christopher G. Willett et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models
Farbod Shojaei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
fdrtool: a versatile R package for estimating local and tail area-based false discovery rates
Korbinian Strimmer
BIOINFORMATICS (2008)
Circulating biomarkers of bevacizumab activity in patients with breast cancer
Neelima Denduluri et al.
CANCER BIOLOGY & THERAPY (2008)
Pathways Mediating Resistance to Vascular Endothelial Growth Factor - Targeted Therapy
Lee M. Ellis et al.
CLINICAL CANCER RESEARCH (2008)
Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness
Seth Politano et al.
CLINICAL COLORECTAL CANCER (2008)
Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies
Farbod Shojaei et al.
DRUG RESISTANCE UPDATES (2008)
Bevacizumab Beyond Progression: Does This Make Sense?
Lee M. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first- line treatment of metastatic colorectal cancer: Updated results from the BICC-C study
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
Axel Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The role of myeloid cells in the promotion of tumour angiogenesis
Craig Murdoch et al.
NATURE REVIEWS CANCER (2008)
Anti-PIGF inhibits growth of VEGF(R)-Inhibitor-Resistant tumors without affecting healthy vessels
Christian Fischer et al.
CELL (2007)
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma
Kimberly A. Varker et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
A phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer
J. Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest
Alfredo Falcone et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM)
E. Maiello et al.
ANNALS OF ONCOLOGY (2006)
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients
CG Willett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter study of the Gruppo Oncologico Dell'Italia Meridionale
G Colucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
IL-16 activates plasminogen-plasmin system and promotes human eosinophil migration into extracellular matrix via CCR3-chemokine-mediated signaling and by modulating CD4 eosinophil expression
C Ferland et al.
JOURNAL OF IMMUNOLOGY (2004)
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
DJ Ceradini et al.
NATURE MEDICINE (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation
YW Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as flrst-line therapy for advanced colorectal cancer
K Bouzid et al.
ANNALS OF ONCOLOGY (2003)
Peripheral blood endothelial progenitor cells are derived from monocyte/macrophages and secrete angiogenic growth factors
J Rehman et al.
CIRCULATION (2003)
The positive false discovery rate: A Bayesian interpretation and the q-value
JD Storey
ANNALS OF STATISTICS (2003)
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer
P Leonard et al.
BRITISH JOURNAL OF CANCER (2002)
Vascular and haematopoietic stem cells:: Novel targets for anti-angiogenesis therapy?
S Rafii et al.
NATURE REVIEWS CANCER (2002)
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel
ML Rothenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Evidence of IL-18 as a novel angiogenic mediator
CC Park et al.
JOURNAL OF IMMUNOLOGY (2001)
Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo
XH Xin et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
分享论文
